📊 PRTA Key Takeaways
Is Prothena Corp. Public Ltd. Co (PRTA) a Good Investment?
Prothena exhibits severe operational distress with minimal revenue of $9.7M declining 31.5% YoY against massive operating losses of -$214.6M, resulting in negative cash burn of -$163.6M annually. The company is spending over $22 for every $1 of revenue generated, indicating a fundamentally broken business model. With approximately 1.9 years of cash runway remaining at current burn rates, the deteriorating trajectory presents high extinction risk without successful capital raise or clinical/commercial breakthroughs.
Why Buy Prothena Corp. Public Ltd. Co Stock? PRTA Key Strengths
- Strong balance sheet with $307.5M cash and only $46.3M liabilities, providing near-term financial flexibility
- Zero long-term debt eliminates refinancing risk and preserves capital raising capacity
- Exceptional liquidity position with 7.72x current ratio ensuring short-term solvency
PRTA Stock Risks: Prothena Corp. Public Ltd. Co Investment Risks
- Catastrophic unprofitability with -2520.6% net margin and -$163.6M annual operating cash burn
- Collapsing revenue base of $9.7M with 31.5% YoY decline suggests failed commercial product strategy or lack of approved assets
- Approximately 1.9 years of cash runway at current burn rate creates existential risk without profitability inflection or successful capital raise
Key Metrics to Watch
- Monthly operating cash burn rate and runway extension timeline
- Revenue stabilization and new product approvals or commercial launch success
- Operating loss reduction and achievement of cash flow breakeven milestones
Prothena Corp. Public Ltd. Co (PRTA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.72x current ratio provides a solid financial cushion.
PRTA Profit Margin, ROE & Profitability Analysis
PRTA vs Healthcare Sector: How Prothena Corp. Public Ltd. Co Compares
How Prothena Corp. Public Ltd. Co compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prothena Corp. Public Ltd. Co Stock Overvalued? PRTA Valuation Analysis 2026
Based on fundamental analysis, Prothena Corp. Public Ltd. Co has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prothena Corp. Public Ltd. Co Balance Sheet: PRTA Debt, Cash & Liquidity
PRTA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prothena Corp. Public Ltd. Co's revenue has declined by 33% over the 5-year period, indicating business contraction. The most recent EPS of $-2.76 indicates the company is currently unprofitable.
PRTA Revenue Growth, EPS Growth & YoY Performance
PRTA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $970.0K | -$36.5M | $-0.68 |
| Q2 2025 | $4.4M | -$5.4M | $-0.10 |
| Q1 2025 | $50.0K | -$60.2M | $-1.12 |
| Q3 2024 | $970.0K | $21.9M | $0.38 |
| Q2 2024 | $4.0M | -$5.4M | $-0.10 |
| Q1 2024 | $50.0K | -$46.9M | $-0.89 |
| Q3 2023 | $1.5M | $21.9M | $0.38 |
| Q2 2023 | $1.3M | -$36.3M | $-0.88 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prothena Corp. Public Ltd. Co Dividends, Buybacks & Capital Allocation
PRTA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prothena Corp. Public Ltd. Co (CIK: 0001559053)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRTA
What is the AI rating for PRTA?
Prothena Corp. Public Ltd. Co (PRTA) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRTA's key strengths?
Claude: Strong balance sheet with $307.5M cash and only $46.3M liabilities, providing near-term financial flexibility. Zero long-term debt eliminates refinancing risk and preserves capital raising capacity.
What are the risks of investing in PRTA?
Claude: Catastrophic unprofitability with -2520.6% net margin and -$163.6M annual operating cash burn. Collapsing revenue base of $9.7M with 31.5% YoY decline suggests failed commercial product strategy or lack of approved assets.
What is PRTA's revenue and growth?
Prothena Corp. Public Ltd. Co reported revenue of $9.7M.
Does PRTA pay dividends?
Prothena Corp. Public Ltd. Co does not currently pay dividends.
Where can I find PRTA SEC filings?
Official SEC filings for Prothena Corp. Public Ltd. Co (CIK: 0001559053) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRTA's EPS?
Prothena Corp. Public Ltd. Co has a diluted EPS of $-4.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRTA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Prothena Corp. Public Ltd. Co has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRTA stock overvalued or undervalued?
Valuation metrics for PRTA: ROE of -87.0% (sector avg: 15%), net margin of -2,520.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRTA stock in 2026?
Our dual AI analysis gives Prothena Corp. Public Ltd. Co a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRTA's free cash flow?
Prothena Corp. Public Ltd. Co's operating cash flow is $-163.6M, with capital expenditures of $110.0K. FCF margin is -1,690.3%.
How does PRTA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,520.6% (avg: 12%), ROE -87.0% (avg: 15%), current ratio 7.72 (avg: 2).